Search | Clinical Trials Finder

Conditions: Sleep Disturbance, Sleep Wake Disorders, Sleep Disorder
Interventions: TranS-C; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Healthy Participants
Interventions: AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Ursodiol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prader-Willi Syndrome
Interventions: Cannabidiol Oral Solution; Drug
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Obese
Interventions: HU6 Tablet, HU6 Capsule; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Obesity, Overweight
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 39 more

Conditions: Obesity, Weight Gain, Food Preferences
Interventions: Broth; Other
Lead sponsor: USDA, Western Human Nutrition Research Center; Federal
Eligibility: 19 Years to 50 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Davis, California

Conditions: Diabetes Melliuts, Type 2
Interventions: Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 17
States / cities: Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more

Conditions: Insulin Sensitivity, Fat; Liver
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 45 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV-1-infection, Frailty, Impaired Physical Function, Abdominal Obesity, Aging
Interventions: Tesamorelin, Placebo, Exercise; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more

Conditions: Cardiomyopathy
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: ABBV-295, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Type 2 Diabetes Mellitus, Exercise, Obesity, Behavioral Research
Interventions: Behavioral counseling plus "telephone helpline"; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Severe Obesity
Interventions: unweighting using Alter-G Anti-Gravity Treadmill, normal weight using Alter-G Anti-Gravity Treadmill; Device
Lead sponsor: Texas Tech University; Other
Eligibility: 20 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Type 2 Diabetes
Interventions: Salsalate, Placebo; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 16
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Winter Park, Florida + 12 more

Conditions: Insulin Resistance
Interventions: (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose, Placebo; Drug · Other
Lead sponsor: EncuraGen, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Overweight, Obesity
Interventions: Standard Diet, Ketogenic Diet, Placebo, Nicotinamide Riboside; Other · Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Overweight
Interventions: Maridebart cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Anniston, Alabama • Daphne, Alabama • Mobile, Alabama + 57 more

Conditions: Inflammation, Inflammatory Response
Interventions: Marine Lipid Oil Concentrate, Dietary Supplement, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Hypotension
Interventions: Phenylephrine bolus, phenylephrine infusion; Drug
Lead sponsor: IWK Health Centre; Other
Eligibility: 18 Years and older · Female only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity, Sarcopenic Obesity, Sarcopenia, Aging, Sedentary Lifestyle
Interventions: Oxytocin nasal spray, Placebo nasal spray; Drug
Lead sponsor: Sara Espinoza; Other
Eligibility: 60 Years to 99 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pediatric Obesity, Meal Timing
Interventions: Meal-timing; Other
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 13 Years to 19 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Improving Sleep Health in Adults With Overweight or Obesity

A Study of Pitolisant in Participants With Prader-Willi Syndrome

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

Safety and Pharmacokinetics of HU6

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Effects of Monosodium Glutamate on Energy Balance and Eating Behavior

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Race Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

Reversal of Obesity Cardiomyopathy

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Project Diabetes: Prescription for Healthy Living

Adherence to Walking on an Alter G Anti-Gravity Treadmill

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation

Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)

The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity

Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity